NCT04323748 (NYMC207) is a Phase 1 clinical trial of rituxan in Immune Thrombocytopenic Purpura, sponsored by New York Medical College.

Who is sponsoring NCT04323748?

NCT04323748 is sponsored by New York Medical College.

What drugs are being tested in NCT04323748?

Interventions in NCT04323748: rituxan.

What condition does NCT04323748 study?

NCT04323748 studies Immune Thrombocytopenic Purpura.

Is NCT04323748 still recruiting?

NCT04323748 is currently recruiting now. Last updated 15 April 2026.

Last reviewed 2026-04-15 · How we verify

NCT04323748: NYMC207

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dose Dense Rituximab for High Risk Newly Diagnosed Acute Immune Thrombocytopenic Purpura

Recruiting now Phase 1 Last updated 15 April 2026

What this trial tests

Phase 1 trial testing rituxan in Immune Thrombocytopenic Purpura in 20 participants. Currently enrolling.

Timeline

24 February 2021

Primary endpoint
31 July 2026

31 July 2027

Quick facts

Lead sponsor	New York Medical College
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	24 February 2021
Primary completion	31 July 2026
Estimated completion	31 July 2027
Sites	1 location across United States

Drugs / interventions tested

rituxan (rituxan) — full drug profile →

Conditions studied

Immune Thrombocytopenic Purpura — all drugs for Immune Thrombocytopenic Purpura →

Sponsor

New York Medical College

Who can join

Adults 1 to 21, any sex, with Immune Thrombocytopenic Purpura. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine if a dose dense administration of Rituximab in newly diagnosed acute immune thrombocytopenic purpura (ITP) and determine relapse rate following this treatment. Correlative studies will be performed as outlined in the appendices. Quality of Life will be measured using the KIT as outlined in the protocol.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Emerging therapeutic advances for immune thrombocytopenia: highlights from selected early‑phase and pivotal trials at the 2025 ASH annual meeting.
Cao L, Wang Z, Xiang Q. · · 2026 · PMID 42210349 · DOI 10.1186/s40164-026-00781-5

Verify or expand the search:

Other New York Medical College trials

Trials by the same sponsor.

NCT07225972 — Phase 3 Randomized Trial for Refractory ADV or CMV Infection With Family Matched CTLs and Standard of Care (SOC) vs SOC · Phase 3 · not yet recruiting
NCT06617286 — CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma · Phase 1, PHASE2 · not yet recruiting
NCT07013565 — Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL · Phase 2 · active not recruiting
NCT05987124 — Defibrotide Dose-escalation for SOS Post-HSCT · Phase 2 · recruiting
NCT05564598 — CMV CTLs in Neonates With CMV Infection · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04323748 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by New York Medical College
Last refreshed: 15 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04323748.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing